Clinical trials: Hypertrophic Cardiomyopathies
Apical Hypertrophic Cardiomyopathy
Surgical Treatment of the Patients With Restrictive Phenotype of the Hypertrophic Cardiomyopathy Without LVOT Obstruction
Hypertrophic cardiomyopathy - is an inherited disease characterized by pronounced genetic and phenotypic heterogeneity. There are two most common anatomic variants of cardiac hypertrophy: subaortic and submitral phenotypes.
- Trial name
- NCT06977646
- Testing
- Surgical transaortic left ventricular cavity remodeling in patients with apical hypertrophic cardiomyopathy without left ventricular outflow tract obstruction
- Where
- Russia
- Volunteers
- 50 people
- Sponsor
- Petrovsky National Research Centre of Surgery
Hypertrophic Obstructive Cardiomyopathy \(HOCM\), Neurologic Evaluation
Neurologic Evaluation of Patients After Transapical Beating-Heart Septal Myectomy
The goal of this prospective cohort study is to evaluate the neurologic changes in patients that received transapical beating-heart septal myectomy.
- Conditions
- Hypertrophic Obstructive Cardiomyopathy \(HOCM\), Neurologic Evaluation, Magnetic Resonance Imaging \(MRI\), Transapical Beating-Heart Septal Myectomy
- Trial name
- NCT06078410
- Testing
- Cardiac surgery
- Where
- China
- Volunteers
- 50 people
- Sponsor
- Xiang Wei
Obstructive Hypertrophic Cardiomyopathy (oHCM)
Phase 3 Trial to Evaluate the Efficacy and Safety of Aficamten Compared to Metoprolol Succinate in Adults With Symptomatic oHCM
The purpose of this study is to compare the efficacy and safety of aficamten (CK-3773274) compared with metoprolol succinate in adults with symptomatic hypertrophic cardiomyopathy and left ventricular outflow tract obstruction
- Trial name
- MAPLE-HCM (NCT05767346)
- Testing
- Aficamten (CK-3773274) (5 mg, 10 mg, 15 mg and 20 mg), Metoprolol succinate (50 mg, 100 mg, 150 mg and 200 mg)
- Where
- 71 sites in United States, Brazil and 11 more
- Volunteers
- 175 people
- Sponsor
- Cytokinetics
Hypertrophic Cardiomyopathy
A Study of EDG-7500 in Adults With Hypertrophic Cardiomyopathy (CIRRUS-HCM)
This study is being conducted in order to understand the safety and effects of different doses of EDG-7500 as a single dose in adults with obstructive hypertrophic cardiomyopathy (oHCM) and as multiple doses in adults with…
- Trial name
- NCT06347159
- Testing
- EDG-7500
- Where
- 21 sites in United States
- Volunteers
- 79 people
- Sponsor
- Edgewise Therapeutics, Inc.
Non-obstructive Hypertrophic Cardiomyopathy
A Phase II Clinical Study of HRS-1893 in Non-obstructive Hypertrophic Cardiomyopathy
This study mainly evaluated the safety and tolerability of HRS-1893 in subjects with non-obstructive hypertrophic cardiomyopathy, and the efficacy and plasma concentrations of different dosing regimens in subjects with…
- Trial name
- NCT06816251
- Testing
- HRS-1893
- Where
- China
- Volunteers
- 84 people
- Sponsor
- Shandong Suncadia Medicine Co., Ltd.
Heart Failure, Cardiomyopathies
Towards Understanding the Phenotype of Cardiovascular Disease in CKD - TRUE-Type-CKD Study
Premature cardiovascular disease (CVD) is the leading cause of death in patients with kidney disease (CKD). Excessive cardiac mortality is thought to be secondary to non-atherosclerotic processes, with left ventricular (LV)…
- Conditions
- Heart Failure, Cardiomyopathies, Chronic Kidney Diseases, Hypertrophy, Left Ventricular
- Trial name
- TRUE-TypeCKD (NCT03749551)
- Testing
- cardiac magnetic resonance (CMR) post haemodialysis
- Where
- Germany
- Volunteers
- 276 people
- Sponsor
- Johann Wolfgang Goethe University Hospital
Healthy, Dilated Cardiomyopathy
Molecular and Imaging Studies of Cardiovascular Health and Disease
Biobank is a program which collects biological samples, health information and imaging data from consented patients and stored them at the core facility.
- Conditions
- Healthy, Dilated Cardiomyopathy, Hypertrophic Cardiomyopathy, Ischemic Heart Disease
- Trial name
- Biobank (NCT02804269)
- Testing
- Cardiovascular Magnetic Resonance, Fatmass measurement
- Where
- Singapore
- Volunteers
- 5,000 people, healthy volunteers welcome
- Sponsor
- National Heart Centre Singapore
Hypertrophic Cardiomyopathy
Effect of Losartan in Patients With Nonobstructive Hypertrophic Cardiomyopathy
The purpose of this study is to determine whether taking losartan helps people with hypertrophic nonobstructive cardiomyopathy feel better by decreasing the amount of heart muscle thickening and/or the amount of heart muscle…
- Trial name
- NCT01150461
- Testing
- losartan
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Massachusetts General Hospital
Hypertrophic Cardiomyopathy, Obstructive
Percutaneous Intramyocardial Septal Radiofrequency Ablation for Obstructive Hypertrophic Cardiomyopathy in Children
The primary purpose of this study was to demonstrate the safety and efficacy of percutaneous intramyocardial septal radiofrequency ablation (PIMSRA) in children and assessed its performance and functional outcomes in the…
- Trial name
- NCT06540183
- Testing
- Percutaneous intramyocardial septal radiofrequency ablation
- Where
- China
- Volunteers
- 23 people
- Sponsor
- Xijing Hospital
HCM - Hypertrophic Cardiomyopathy
Effect of Henagliflozin on Myocardial Fibrosis in Non-Obstructive HCM: A Randomized, Double-Blind, Placebo-Controlled Trial Using 68Ga/18F-FAPI PET/CMR
his is a single-center, randomized, double-blind, placebo-controlled clinical trial designed to evaluate the effect of Henagliflozin (an SGLT2 inhibitor) on myocardial fibrosis burden in patients with non-obstructive hypertrophic…
- Trial name
- NCT07294495
- Testing
- Henagliflozin (SGLT2 Inhibitor)
- Where
- China
- Volunteers
- 150 people
- Sponsor
- Shanghai East Hospital
Cardiomyopathy, Hypertrophic, Muscular Dystrophy, Oculopharyngeal
Study of Muscle Abnormalities in Patients With Specific Genetic Mutations
Hypertrophic cardiomyopathy (HCM) is a genetically inherited disease affecting the heart. It causes thickening of heart muscle, especially the chamber responsible for pumping blood out of the heart, the left ventricle.
- Trial name
- NCT00001871
- Where
- United States
- Volunteers
- 80 people
- Sponsor
- National Heart, Lung, and Blood Institute (NHLBI)
Hypertrophic Cardiomyopathy (HCM)
Mavacamten to Aficamten Transition in Patients With Obstructive Hypertrophic Cardiomyopathy
This is an investigator-initiated two-center study. The goal of this study is to investigate the feasibility, safety and efficacy outcomes of a seamless transition from mavacamten to aficamten in patients with obstructive…
- Trial name
- CMI-SWITCH (NCT07600177)
- Testing
- Aficamten
- Where
- 2 sites in United States
- Volunteers
- 40 people
- Sponsor
- Oregon Health and Science University
Hypertrophic Cardiomyopathy, Depression
Efficacy of Psychotherapy for Improving Quality of Life in Patients With Hypertrophic Cardiomyopathy and Depression
A Study to evaluate the efficacy of psychotherapy for easing the cardiac symptoms and improving and quality of life in patients with hypertrophic cardiomyopathy accompanied with depression
- Conditions
- Hypertrophic Cardiomyopathy, Depression, Anxiety, Psychotherapy
- Trial name
- NCT03706001
- Testing
- Psychotherapy
- Volunteers
- 100 people
- Sponsor
- Xijing Hospital
Hypertrophic Cardiomyopathy
Valsartan for Attenuating Disease Evolution In Early Sarcomeric HCM
The purpose of this trial is to determine whether treatment with valsartan will have beneficial effect in early hypertrophic cardiomyopathy (HCM) by assessing many domains that reflect myocardial structure, function and…
- Trial name
- VANISH (NCT01912534)
- Testing
- Valsartan
- Where
- 15 sites in United States, Canada
- Volunteers
- 211 people
- Sponsor
- Carelon Research
Hypertrophic Cardiomyopathy
Diagnosis of HCM With AI-ECG
The study aims to establish a diagnostic model of hypertrophic cardiomyopathy with artificial intelligence-enhanced electrocardiogram.
- Trial name
- NCT06287892
- Where
- China
- Volunteers
- 10,000 people, healthy volunteers welcome
- Sponsor
- Shanghai Zhongshan Hospital
Hypertrophic Cardiomyopathy
Studying the Effectiveness of Pacemaker Therapy in Children Who Have Thickened Heart Muscle
A heart condition called hypertrophic cardiomyopathy (HCM) causes abnormal thickening of the heart muscle, which obstructs the flow of blood out of the heart.
- Trial name
- NCT00001960
- Testing
- Pacemaker therapy
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- National Heart, Lung, and Blood Institute (NHLBI)
Hypertrophic Cardiomyopathy (HCM)
ReGistry of hypeRtrophic cArDIomyopathy: Regional fEatures, geNeTics and Course
This study is envisioned as the very first of its kind in the Russian Federation, aiming to provide a comprehensive characterization of the clinical spectrum and disease burden, focusing on the epidemiology and progression of HCM…
- Trial name
- GRADIENT (NCT07295613)
- Where
- 2 sites in Russia
- Volunteers
- 1,400 people
- Sponsor
- Central State Medical Academy
Hypertrophy, Left Ventricular, Hypertension
Effect of a Targeted Notification and Clinical Support Pathway on Individuals With Left Ventricular Hypertrophy
The electronic health record contains vast amounts of cardiovascular data, including potential clues that an individual may have unrecognized cardiac conditions.
- Conditions
- Hypertrophy, Left Ventricular, Hypertension, Cardiomyopathies
- Trial name
- NOTIFY-LVH (NCT05713916)
- Testing
- Intervention: Population Health Coordinator
- Where
- United States
- Volunteers
- 648 people
- Sponsor
- Massachusetts General Hospital
Hypertrophic Cardiomyopathy (HCM)
LA-HCM Study : Rivaroxaban for Antithrombotic Prevention in Hypertrophic Cardiomyopathy Patients With Abnormal Left Atrial Strain.
Hypertrophic cardiomyopathy (HCM) is a common (> 1/500 in the general adult population) genetically transmitted disease impacting markedly patients' lives from the early ages to the latest.
- Trial name
- LA-HCM (NCT07202897)
- Testing
- Anticoagulant treatment Rivaroxaban, Best medical therapy
- Where
- 17 sites in France
- Volunteers
- 532 people
- Sponsor
- Rennes University Hospital
Obstructive Hypertrophic Cardiomyopathy
A Study to Assess the Safety of Mavacamten in Korean Patients With Symptomatic Obstructive Hypertrophic Cardiomyopathy
The purpose of this observational post-marketing surveillance study is to assess the real-world safety of mavacamten for the treatment of symptomatic obstructive hypertrophic cardiomyopathy (oHCM) in adult participants in Korea.
- Trial name
- NCT06146660
- Testing
- Mavacamten
- Where
- 2 sites in South Korea
- Volunteers
- 600 people
- Sponsor
- Bristol-Myers Squibb